Phase I Study of Aerosolized SLIT Cisplatin in the Treatment of Patients with Carcinoma of the Lung
Open Access
- 15 April 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (8), 2414-2421
- https://doi.org/10.1158/1078-0432.ccr-06-1480
Abstract
Purpose: To investigate the safety and pharmacokinetics of aerosolized Sustained Release Lipid Inhalation Targeting (SLIT) Cisplatin in patients with lung carcinoma. Experimental Design: Phase I, dose-escalating study of SLIT Cisplatin given in two sessions daily. Safety data, including laboratory variables, adverse events, pulmonary function tests, and radiographic imaging, were collected and analyzed for all patients to determine toxicity. Pharmacokinetic monitoring was done during the first course. Results: Seventeen patients and one tracheostomy patient on compassionate use received treatment. Aerosolized cisplatin was well tolerated. No dose-limiting toxicity was observed at the maximum delivered dose. Safety data showed no hematologic toxicity, nephrotoxicity, ototoxicity, or neurotoxicity. Most common adverse events were nausea (64.7%), vomiting (47.1%), dyspnea (64.7%), fatigue (64.7%), and hoarseness (47.1%). Pharmacokinetic data showed very low plasma platinum levels only with the longest repeated inhalations. Common Toxicity Criteria grade 2 decrease in forced expiratory volume in one second and diffusing lung capacity for carbon monoxide after one course occurred both in two patients and grade one decrease in forced expiratory volume in one second and diffusing lung capacity for carbon monoxide in six and five patients, respectively. Direct airway deposition via the tracheostomy resulted in clinical deterioration after two cycles best described as bronchitis, completely reversible within days. Overall response: stable disease in 12 patients and progressive disease in 4 patients (one patient received one cycle). Conclusions: Aerosolized liposomal cisplatin was found to be feasible and safe.Keywords
This publication has 29 references indexed in Scilit:
- Standardisation of spirometryEuropean Respiratory Journal, 2005
- Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastasesInternational Journal of Cancer, 2005
- A pilot study of high‐dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0–N3M0 squamous cell carcinoma of the upper aerodigestive tractCancer, 2005
- Clinical Evaluation of the Delivery and Safety of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecin in Patients with Advanced Pulmonary MalignanciesClinical Cancer Research, 2004
- Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medicationsBritish Journal of Clinical Pharmacology, 2003
- Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatinCancer Chemotherapy and Pharmacology, 2002
- Guidelines for Methacholine and Exercise Challenge Testing—1999American Journal of Respiratory and Critical Care Medicine, 2000
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerThe New England Journal of Medicine, 1996
- A paediatric canopy system for aerosol administration and minimized environmental pollutionActa Anaesthesiologica Scandinavica, 1996
- Cisplatin administered by the intracavitary route as treatment for malignant mesotheliomaCancer, 1986